Ozempic

(Semaglutide)

ApprovedPeptide

Semaglutide is used to help people with type 2 diabetes control their blood sugar levels, and it's also used for weight loss in people who are overweight or obese. It works by helping your body use insulin better and reducing your appetite.[2] Ozempic is currently approved and in use across 100 indications[4].[1]

Ozempic is one of 1339 peptide programs targeting NASH/MASH. It is currently in Approved.

100

Indications

557

Total Trials

Active Trials

1,338

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

NASH/MASHApproved

Weight LossRecruiting

ObesityCompleted

Type 1 DiabetesNot yet recruiting

SemaglutideNot yet recruiting

Alcohol Use Disorder (AUD)Completed

Non-Alcoholic Fatty Liver DiseaseCompleted

Endothelial DysfunctionActive, not recruiting

Insulin SecretionActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

NASH/MASHApproved

Approved

Weight LossApproved

Recruiting

ObesityApproved

Completed

Type 1 DiabetesPhase 3

Not yet recruiting

SemaglutideApproved

Not yet recruiting

Alcohol Use Disorder (AUD)Phase 2

Completed

Non-Alcoholic Fatty Liver DiseasePhase 2

Completed

Endothelial DysfunctionApproved

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

Obstructive Sleep ApneaPreclinical

Active, not recruiting

Showing 10 of 100 indications

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

2 2

Biltricide

Bayer

Preclinical

3 3

Dexilant

Takeda

Preclinical

2 4

Minipress

Pfizer

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Alfenta

Jazz Pharmaceuticals

Preclinical

1 7

Valium

Akero Therapeutics

Preclinical

2 8

Intuniv

PPromius Pharma, LLC

Preclinical

1 9

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ANot yet recruiting

Obesity

NCT07319975

Phase 2Not yet recruiting

Type 2 Diabetes Mellitus

NCT07187856

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06778967

N/ARecruiting

Body Weight

NCT06989203

Post-ApprovalNot yet recruiting

Semaglutide

NCT07165158

N/ARecruiting

Probiotic Intervention

NCT06989177

Clinical

Trials by Indication[1]

Type 2 Diabetes53 trials

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Completed· Novo Nordisk logo

Novo Nordisk··NCT04083820·521 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT03457012·462 enrolled

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05144984·500 enrolled

Show 50 more trials

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05486065·245 enrolled

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02147431·38 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03929679·218 enrolled

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03191396·577 enrolled

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04287179

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03552757·1,210 enrolled

A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment

Completed· Novo Nordisk logo

Novo Nordisk··NCT06478550·304 enrolled

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02207374·601 enrolled

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT01720446·3,297 enrolled

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Active, not recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06184568·349 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)

Completed· Novo Nordisk logo

Novo Nordisk··NCT04261933·789 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03631186·215 enrolled

Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk··NCT06507475·209 enrolled

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03689374·2,274 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443191·50 enrolled

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02648204·1,201 enrolled

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813912·148 enrolled

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

Unknown status·KKirsi Pietiläinen·Phase 4·NCT04854083·50 enrolled

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02692716·3,183 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05316662·187 enrolled

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05478252·388 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04067999·230 enrolled

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02254291·308 enrolled

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Enrolling by invitation·SSteno Diabetes Center Copenhagen·Phase 4·NCT06954090·50 enrolled

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07400107·1,000 enrolled

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01686945·107 enrolled

A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)

Completed· Novo Nordisk logo

Novo Nordisk··NCT05468632·314 enrolled

Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 4·NCT05303857·107 enrolled

A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 2·NCT06974825·67 enrolled

DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy

Completed· Novo Nordisk logo

Novo Nordisk··NCT05755360·291 enrolled

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT01923181·632 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03648281·333 enrolled

Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

Recruiting·GGT Metabolic Solutions, Inc.·N/A·NCT07317115·20 enrolled

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Not yet recruiting·GGuangdong Raynovent Biotech Co., Ltd·Phase 3·NCT07139548·600 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Completed· Novo Nordisk logo

Novo Nordisk··NCT03876015·215 enrolled

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

Active, not recruiting·—··NCT06980623·26,000 enrolled

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT04153929·413 enrolled

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Completed· Novo Nordisk logo

Novo Nordisk··NCT06351748·34,238 enrolled

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02827708·324 enrolled

Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05950516·478 enrolled

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Unknown status·—·Phase 4·NCT05597202·22 enrolled

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06403761·158 enrolled

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

Completed·—·N/A·NCT05078255·61 enrolled

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03789578·30 enrolled

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Recruiting·UUniversity of Washington·Phase 4·NCT05780905·50 enrolled

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Unknown status·SSteno Diabetes Center Copenhagen·Phase 4·NCT04061200·80 enrolled

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT04094415·581 enrolled

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Completed· Novo Nordisk logo

Novo Nordisk··NCT05443334·465 enrolled

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03018028·243 enrolled

O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

Completed· Novo Nordisk logo

Novo Nordisk··NCT05716724·288 enrolled

Semaglutide37 trials

A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03010475·41 enrolled

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05766709·53 enrolled

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01866748·170 enrolled

Show 34 more trials

A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02064348·168 enrolled

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02557620·113 enrolled

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02070510·52 enrolled

The Effects of Semaglutide on Body Composition and Performance in Military Personnel

Withdrawn·—·Phase 4·NCT06468748

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02920385·45 enrolled

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04878406·24 enrolled

Semaglutide and Vascular Regeneration

Unknown status·CCanadian Medical and Surgical Knowledge Translation Research Group·Phase 4·NCT05870462·100 enrolled

Semaglutide in Auto-HSCT

Not yet recruiting·KKlaus Gottlob Müller·Phase 2·NCT06449625·40 enrolled

Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02060266·7 enrolled

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06699329·38 enrolled

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Completed·HHospital Israelita Albert Einstein··NCT06154486·30 enrolled

The Effect of Semaglutide on Bone Health

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 4·NCT07165158·150 enrolled

A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

Not yet recruiting·BBostal Drug Delivery Co., Ltd·Phase 1·NCT06422624·14 enrolled

Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02231684·42 enrolled

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06041217·242 enrolled

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02022254·24 enrolled

Real-world Health Outcomes in Canadian Patients Using Semaglutide

Completed·LLMC Diabetes & Endocrinology Ltd.··NCT04175665·1,133 enrolled

Effect Of Semaglutide In Coronary Atheroma Plaque

Unknown status·FFundación Instituto de Estudios de Ciencias de la Salud de Castilla y León·Phase 3·NCT05071417·120 enrolled

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03611582·611 enrolled

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Completed·SSabyasachi Sen·Phase 4·NCT04126603·10 enrolled

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03598621·68 enrolled

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

Terminated·SSansum Diabetes Research Institute·Phase 4·NCT04938388·12 enrolled

"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."

Unknown status·—·Phase 1·NCT05249881·300 enrolled

The Effect of Weekly Semaglutide Treatment on Energy Expenditure

Completed·SShenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences·N/A·NCT06390501·60 enrolled

Treating PCOS With Semaglutide vs Active Lifestyle Intervention

Completed·UUniversity of Colorado, Denver·Phase 2/3·NCT03919929·60 enrolled

A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

Recruiting·AActimed Therapeutics Ltd·Phase 2·NCT07101939·120 enrolled

Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 2/3·NCT06387199·26 enrolled

Genetics of the Acute Response to Oral Semaglutide

Recruiting·MMedical University of Bialystok·N/A·NCT05340868·1,000 enrolled

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05227196·546 enrolled

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05046873·16 enrolled

A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05784402·264 enrolled

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04097600·274 enrolled

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Not yet recruiting·—·Phase 4·NCT07483801·112 enrolled

Semaglutide in CFRD

Completed·UUniversity of Minnesota·Phase 2/3·NCT05788965·8 enrolled

Obesity12 trials

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03842202·72 enrolled

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05671653·32 enrolled

The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT04263415·30 enrolled

Show 9 more trials

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

Not yet recruiting·—·N/A·NCT07319975·48 enrolled

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07081178·555 enrolled

Semaglutide in Treatment of Obesity

Active, not recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT06604624·462 enrolled

Tailoring Obesity Treatment Trial

Suspended·EEsbjerg Hospital - University Hospital of Southern Denmark·Phase 2/3·NCT06619015·40 enrolled

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05236517·60 enrolled

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06745284·60 enrolled

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT04969939·120 enrolled

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07293325·66 enrolled

Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled

Type 2 Diabetes Mellitus10 trials

A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04515849·248 enrolled

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06579105·406 enrolled

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

Not yet recruiting·—·N/A·NCT06555146·15 enrolled

Show 7 more trials

Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Not yet recruiting· Novo Nordisk logo

Novo Nordisk··NCT05689372·600 enrolled

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Not yet recruiting·PProGen. Co., Ltd.·Phase 2·NCT07187856·80 enrolled

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03086330·302 enrolled

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03951753·117 enrolled

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Unknown status·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06256549·272 enrolled

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06778967·1,100 enrolled

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

Completed·UUniversity Medical Centre Ljubljana·Phase 3·NCT06489457·25 enrolled

Overweight7 trials

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03548935·1,961 enrolled

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04251156·375 enrolled

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03548987·902 enrolled

Show 4 more trials

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03707990·88 enrolled

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT05822830·751 enrolled

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT03693430·304 enrolled

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03600480·96 enrolled

60 more indications

Weight loss5 trials

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Not yet recruiting·HHangzhou Jiuyuan Gene Engineering Co. Ltd.,·Phase 3·NCT06633783·370 enrolled

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT06571383·500 enrolled

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Completed·HHillel Yaffe Medical Center··NCT07043361·5,300 enrolled

Show 2 more trials

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Recruiting·MMcMaster University·Phase 4·NCT06852391·74 enrolled

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Not yet recruiting·BBiophytis·Phase 2·NCT07411378·164 enrolled

Chronic Kidney Disease3 trials

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04865770·106 enrolled

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06717698·465 enrolled

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07391267·90 enrolled

Heart Failure3 trials

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Recruiting·UUniversity Medical Centre Ljubljana·Phase 1/2·NCT06541509·10 enrolled

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Completed·—··NCT06914141·28,118 enrolled

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Completed·—··NCT06914102·58,387 enrolled

Hepatitis2 trials

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Completed· Gilead logo

Gilead·Phase 2·NCT03987074·109 enrolled

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05877547·381 enrolled

Fatty Liver Disease2 trials

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Not yet recruiting·IInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval·N/A·NCT06764056·120 enrolled

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

Recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06884293·470 enrolled

Kidney Transplant2 trials

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT05938712·20 enrolled

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Terminated·GGeisinger Clinic·Phase 3·NCT04741074·15 enrolled

Hepatic Impairment2 trials

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02210871·44 enrolled

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02016911·56 enrolled

Clinical Trial2 trials

A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT00813020·44 enrolled

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05232708·18 enrolled

Body Weight2 trials

Protein Supplementation Intervention on Body Weight

Recruiting·CChinese Academy of Sciences·N/A·NCT06989203·140 enrolled

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06388187·300 enrolled

Type 1 Diabetes2 trials

GLP-1 RA for Stage 1 Type 1 Diabetes

Not yet recruiting·—·Phase 2·NCT07430332·15 enrolled

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT05819138·60 enrolled

PreDiabetes2 trials

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 4·NCT05119179·300 enrolled

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Completed·JJan Frystyk·Phase 2·NCT05193578·154 enrolled

Diabetes Mellitus2 trials

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

Recruiting·MMedanta, The Medicity, India·N/A·NCT06060392·50 enrolled

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02453711·957 enrolled

Cardiovascular2 trials

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

Recruiting·—··NCT06301191·50 enrolled

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Completed·—··NCT07096063·887,132 enrolled

Non-Alcoholic Steatohepatitis2 trials

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT05016882·698 enrolled

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02970942·320 enrolled

Double-blind1 trial

A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01766245·28 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Completed·—··NCT05768945·742,670 enrolled

Tics1 trial

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01272973·96 enrolled

Motor Function1 trial

Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions

Active, not recruiting·MMayo Clinic·Phase 4·NCT06801015·30 enrolled

Atorvastatin1 trial

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Type 2 Diabetic Patients1 trial

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Unknown status·UUniversity Hospital Sestre Milosrdnice·Phase 4·NCT06243536·60 enrolled

Gastric Emptying1 trial

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02079870·30 enrolled

Peripheral Arterial Disease1 trial

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04560998·792 enrolled

Impaired Renal Function1 trial

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02014259·71 enrolled

Trial1 trial

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03144271·58 enrolled

Alcoholic Fatty Liver Disease1 trial

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04944992·145 enrolled

Liver Transplant1 trial

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Recruiting·VVirginia Commonwealth University·Phase 2·NCT05424003·50 enrolled

Liver Disease1 trial

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06409130·270 enrolled

Lung Disease1 trial

Feasibility of Semaglutide in Advanced Lung Disease

Recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT05746039·8 enrolled

Atrial Fibrillation1 trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Recruiting·UUniversity of Chicago·Phase 3·NCT06499857·200 enrolled

Ischemic stroke1 trial

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

Recruiting·—·Phase 2·NCT05630586·380 enrolled

ART1 trial

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05129891·384 enrolled

Klinefelter Syndrome1 trial

Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome

Recruiting·GGeorgios Papadakis·Phase 3·NCT05586802·150 enrolled

Probiotic Intervention1 trial

Probiotic Intervention on Body Weight

Recruiting·CChinese Academy of Sciences·N/A·NCT06989177·140 enrolled

Menopause1 trial

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05153564·27 enrolled

Cognition1 trial

Semaglutide and Cognition in Healthy Volunteers

Completed·UUniversity of Oxford·N/A·NCT06363487·70 enrolled

Parkinson's Disease1 trial

GLP1R in Parkinson's Disease

Unknown status·OOslo University Hospital·Phase 2·NCT03659682·120 enrolled

Myocardial Infarction1 trial

Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT06557811·88 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Recruiting·YYale University·Phase 2·NCT05067621·60 enrolled

T1DM1 trial

Triple Therapy in T1DM

Active, not recruiting·SState University of New York at Buffalo·Phase 2/3·NCT03899402·78 enrolled

Oral1 trial

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06642584·90 enrolled

Pathophysiology1 trial

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Active, not recruiting·RRegion Skane·Phase 2·NCT04451837·200 enrolled

Cardiovascular Disease1 trial

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Recruiting·SSteno Diabetes Center Copenhagen·Phase 3·NCT06082063·2,000 enrolled

Weight Change1 trial

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Unknown status·HHuashan Hospital·Phase 4·NCT05616052·80 enrolled

Concentration1 trial

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05689099·20 enrolled

Polycystic Ovary Syndrome1 trial

Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

Recruiting·PPeking University First Hospital·Phase 4·NCT05702905·75 enrolled

Systemic Scleroderma1 trial

Subcutaneous Semaglutide in Systemic Scleroderma

Recruiting·SSecond Xiangya Hospital of Central South University·Phase 1·NCT06149260·10 enrolled

Endothelial Dysfunction1 trial

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

Completed·GGeneral and Teaching Hospital Celje·Phase 4·NCT05857085·90 enrolled

Metabolic Syndrome1 trial

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Recruiting·UUniversity Medical Center, Kazakhstan·Phase 4·NCT06410352·220 enrolled

Dapagliflozin1 trial

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05429593·152 enrolled

Drug1 trial

Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

Completed·VVivani Medical, Inc·Phase 1·NCT05670379·24 enrolled

Metabolic Disease1 trial

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Withdrawn·CCorEvitas··NCT06354101

Major Depressive Disorder1 trial

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04466345·72 enrolled

Stroke1 trial

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Completed·—·Phase 2·NCT05920889·140 enrolled

Medication1 trial

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Active, not recruiting·AAnders Fink-Jensen, MD, DMSci·Phase 4·NCT04892199·104 enrolled

Treatment1 trial

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Recruiting·WWoman's·Phase 4·NCT04873050·102 enrolled

Tobacco Use1 trial

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

Recruiting·UUniversity of Oklahoma·Phase 4·NCT06986993·40 enrolled

Polycystic Ovarian Syndrome1 trial

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Withdrawn·MMethodist Health System·Phase 1·NCT06222437

Obese Patients1 trial

Semaglutide Use in Elderly Obese Patients

Completed·SState University of New York at Buffalo·Phase 2·NCT05302596·16 enrolled

Pulmonary Embolism1 trial

Semaglutide Use in Acute Pulmonary Embolism

Completed·IImperial College London··NCT06118203·18 enrolled

Unspecified3 trials

Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets

Unknown status·UUniversity of Nottingham·Phase 4·NCT05606471·45 enrolled

Special Use - Results Surveillance on Long-term Use With Wegovy®

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT06283667·1,000 enrolled

Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

Completed· Novo Nordisk logo

Novo Nordisk··NCT04469855·3,217 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 5, 2017

OZEMPIC

NDA NDA209637

Jun 4, 2021

WEGOVY

NDA NDA215256

Dec 9, 2024

RYBELSUS

NDA NDA213051

Dec 22, 2025

WEGOVY

NDA NDA218316

Sources

References

[1]
ClinicalTrials.gov — 557 trial records for Semaglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ozempic drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Semaglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Semaglutide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218316). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Ozempic. U.S. Food & Drug Administration.
[7]
PubMed — 7 publications indexed for Semaglutide. U.S. National Library of Medicine.
[8]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GLP-1 Receptor Agonist[3]
Modality: Peptide[3]
Highest Phase: Approved[1]
Company: Novo Nordisk

Patent Landscape[6]

Patent Cliff

Feb 27, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10357616Jan 20, 2026

9616180Jan 20, 2026

9861757Jan 20, 2026

10376652Jan 20, 2026

9108002Jan 20, 2026

36 more patents

8536122Mar 20, 2026

9775953Jul 17, 2026

10220155Jul 17, 2026

11097063Jul 17, 2026

8920383Jul 17, 2026

RE46363Aug 3, 2026

9687611Feb 27, 2027

9457154Sep 29, 2027

8129343Dec 5, 2031

10960052Dec 16, 2031

10086047Dec 16, 2031

9278123Dec 16, 2031

11382957Dec 16, 2031

9132239Feb 1, 2032

11759501Mar 15, 2033

10933120Mar 15, 2033

11759502Mar 15, 2033

11759503Mar 15, 2033

12594326Mar 15, 2033

11033499Jun 19, 2033

9764003Jun 21, 2033

10335462Jun 21, 2033

10278923May 2, 2034

12239739May 2, 2034

12514822May 2, 2034

12569543Apr 28, 2037

11752198Aug 24, 2038

12214017Aug 24, 2038

10888605Aug 24, 2038

12295988Oct 10, 2038

12551536Oct 10, 2038

12029779Oct 10, 2038

11833248Feb 1, 2039

12396953Feb 1, 2039

11478533May 13, 2040

11318191Feb 17, 2041

Key Publications[7]

Semaglutide in Chronic Kidney Disease: FLOW Trial Results

N Engl J MedMay 24, 2024DOI: 10.1056/NEJMoa2403347

Semaglutide and MASH: Phase 3 Histological Outcomes

N Engl J MedMar 14, 2024DOI: 10.1056/NEJMoa2311203

Oral Semaglutide Versus Injectable GLP-1 Receptor Agonists: A Systematic Review

Lancet Diabetes EndocrinolOct 15, 2023DOI: 10.1016/S2213-8587(23)00263-1

Semaglutide Effects on Heart Failure Outcomes in Obesity: SELECT Trial

N Engl J MedDec 28, 2022DOI: 10.1056/NEJMoa2215256

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

N Engl J MedNov 10, 2022DOI: 10.1056/NEJMoa2215760

Once-Weekly Semaglutide in Adults with Overweight or Obesity

N Engl J MedJun 2, 2022DOI: 10.1056/NEJMoa2206038

Semaglutide 2.4 mg and Cardiometabolic Risk Reduction: STEP Program Results

JAMAFeb 10, 2021DOI: 10.1001/jama.2021.1831

Ozempic

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes53 trials

Semaglutide37 trials

Obesity12 trials

Type 2 Diabetes Mellitus10 trials

Overweight7 trials

Weight loss5 trials

Chronic Kidney Disease3 trials

Heart Failure3 trials

Hepatitis2 trials

Fatty Liver Disease2 trials

Kidney Transplant2 trials

Hepatic Impairment2 trials

Clinical Trial2 trials

Body Weight2 trials

Type 1 Diabetes2 trials

PreDiabetes2 trials

Diabetes Mellitus2 trials

Cardiovascular2 trials

Non-Alcoholic Steatohepatitis2 trials

Double-blind1 trial

Drug Repurposing1 trial

Tics1 trial

Motor Function1 trial

Atorvastatin1 trial

Type 2 Diabetic Patients1 trial

Gastric Emptying1 trial

Peripheral Arterial Disease1 trial

Impaired Renal Function1 trial

Trial1 trial

Alcoholic Fatty Liver Disease1 trial

Liver Transplant1 trial

Liver Disease1 trial

Lung Disease1 trial

Atrial Fibrillation1 trial

Ischemic stroke1 trial

ART1 trial

Klinefelter Syndrome1 trial

Probiotic Intervention1 trial

Menopause1 trial

Cognition1 trial

Parkinson's Disease1 trial

Myocardial Infarction1 trial

Non-Alcoholic Fatty Liver Disease1 trial

T1DM1 trial

Oral1 trial

Pathophysiology1 trial

Cardiovascular Disease1 trial

Weight Change1 trial

Concentration1 trial

Polycystic Ovary Syndrome1 trial

Systemic Scleroderma1 trial

Endothelial Dysfunction1 trial

Metabolic Syndrome1 trial

Dapagliflozin1 trial

Drug1 trial

Metabolic Disease1 trial

Major Depressive Disorder1 trial

Stroke1 trial

Medication1 trial

Treatment1 trial

Tobacco Use1 trial

Polycystic Ovarian Syndrome1 trial

Obese Patients1 trial

Pulmonary Embolism1 trial

Unspecified3 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Key Publications[7]

Related News